Patent intelligence · US
US 10675246
Orally administrable compositions comprising calcium
Orally administrable compositions comprising calcium
Patent details — US 10675246
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 9, 2020
- Expiration
- Jun 4, 2040
- Applicant
- CEROLIFE LLC
- Claims
- 11
- CPC classes
- A61K, A61K33/06, A61K33/10, A61K9/2027
Quick answer
US 10675246 (Orally administrable compositions comprising calcium) is held by CEROLIFE LLC. Status: granted. Granted Jun 9, 2020. Expires Jun 4, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CEROLIFE LLC
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K33/06, A61K33/10, A61K9/2027, A61K9/2031, A61K9/2054
More from CEROLIFE LLC
Related pharmaceutical patents in our USPTO index.
-
US 12303551
Cellular immunotherapy compositions and uses thereof
granted -
US 12291557
Chimeric TIM4 receptors and uses thereof
granted -
US 11708423
Chimeric engulfment receptor molecules and methods of use
granted -
US 11697689
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
granted -
US 11655282
Chimeric engulfment receptor molecules
granted -
US 10307410
Mcl-1 modulating compounds for cancer treatment
granted -
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
granted
Frequently asked questions
What is US patent 10675246?
US 10675246 (Orally administrable compositions comprising calcium) is held by CEROLIFE LLC. Status: granted. Granted Jun 9, 2020. Expires Jun 4, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10675246?
CEROLIFE LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 10675246 expire?
Our index shows an expiration date of Jun 4, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.